SSG
HRTX icon

Summit Securities Group’s Heron Therapeutics HRTX Stock Holding History

Summit Securities Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-320
Closed -$1K – 755
2024
Q3 		$1K Buy
+320
New +$764 ﹤0.01% 511

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Summit Securities Group's HRTX Position: Q4 2024 in Review

Summit Securities Group sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 320 shares — an estimated $1K sold.

Summit Securities Group first reported a position in HRTX in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Summit Securities Group reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 320 Heron Therapeutics shares in Q4 2024, an estimated $1K.
  • Summit Securities Group first reported a position in Heron Therapeutics in Q3 2024 and held it in 1 quarter.
  • Summit Securities Group's Heron Therapeutics position peaked at $1K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.